Pascal Deschatelets - Apellis Pharmaceuticals CoFounder Officer
| APLS Stock | USD 24.26 0.12 0.50% |
Founder
Dr. Pascal Deschatelets Ph.D. serves as CoFounder, Chief Operating Officer of the Company. Dr. Deschatelets cofounder of our company and has served as our Chief Operating Officer since our inception in 2009. Dr. Deschatelets also cofounded Potentia and served as its Chief Operating Officer from 2001 to September 2016 and is a cofounder of Revon since 2016.
| Age | 55 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://apellis.com |
Pascal Deschatelets Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pascal Deschatelets against Apellis Pharmaceuticals stock is an integral part of due diligence when investing in Apellis Pharmaceuticals. Pascal Deschatelets insider activity provides valuable insight into whether Apellis Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Apellis Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Apellis Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pascal Deschatelets over three months ago Disposition of 874 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 64.1382 subject to Rule 16b-3 | ||
Pascal Deschatelets over six months ago Disposition of 24500 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 3.76 subject to Rule 16b-3 | ||
Pascal Deschatelets over six months ago Disposition of 69107 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 3.76 subject to Rule 16b-3 |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1232) % which means that it has lost $0.1232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9355) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2025. Return On Capital Employed is likely to drop to -0.35 in 2025. At this time, Apellis Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2025, whereas Other Current Assets are likely to drop slightly above 26.2 M in 2025.Similar Executives
| Found 6 records | FOUNDER Age | ||
| Charles Sermon | Mereo BioPharma Group | 56 | |
| Grant Krafft | Acumen Pharmaceuticals | N/A | |
| William Klein | Acumen Pharmaceuticals | N/A | |
| John MBA | Mereo BioPharma Group | 68 | |
| Caleb Finch | Acumen Pharmaceuticals | N/A | |
| Dr JD | Akero Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.12 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Meredith Kaya, Investor President | ||
| Adam Townsend, Chief Commercial Officer | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| Nur Nicholson, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Pr MD, Head Board | ||
| David Acheson, Senior Commercial | ||
| Lukas MD, Chief Officer | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Victoria Brown, Senior President | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Caroline MD, Chief Officer | ||
| Jeffrey Eisele, Chief Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 3.09 B | ||||
| Shares Outstanding | 125.52 M | ||||
| Shares Owned By Insiders | 13.85 % | ||||
| Shares Owned By Institutions | 86.15 % | ||||
| Number Of Shares Shorted | 17.34 M | ||||
| Price To Earning | (6.94) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.